- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04079088
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Oral BIIB061 as Add-On Therapy to Interferon-Beta 1 or Glatiramer Acetate Therapies in Relapsing Multiple Sclerosis
The primary objectives of the study are to evaluate the safety of BIIB061 versus placebo in participants with Relapsing Multiple Sclerosis (RMS), and to evaluate the efficacy of BIIB061 to improve disability outcome versus placebo in participants with RMS.
The secondary objectives of the study are to evaluate the effects of BIIB061 versus placebo on brain magnetic resonance imaging (MRI) markers of remyelination and axon preservation in chronic Multiple Sclerosis lesions and to evaluate the effects of BIIB061 versus placebo on additional measures of improved disability outcome.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Diagnosed with relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS)
- Have a Baseline Expanded Disability Status Scale (EDSS) score of 2.0 to 6.0
- Have a MS disease duration of ≤20 years from first MS symptom(s)
- Must have at least one of the following occurring within 12 months prior to
Day 1/Baseline:
(a) ≥1 clinical relapse(s) or objective disability worsening (as per treating neurologist's judgment) (b) ≥1 Gadolinium (Gd)-enhancing T1 lesion(s) on brain or spinal cord Magnetic Resonance Imaging (MRI) (c) ≥1 new T2 lesion(s) on brain or spinal cord MRI (the reference scan used to detect new T2 lesion formation has to be ≤12 months prior to Day 1/Baseline)
Must have been taking one of the following disease-modifying therapy (DMTs) at a stable dose for at least 12 weeks prior to Day 1/Baseline:
- Interferon-beta1 (IFN-β1): Avonex, Plegridy, Betaferon/Betaseron, Extavia, or Rebif
Glatiramer acetate (Copaxone or Glatopa).
Key Exclusion Criteria:
- A documented history of clinically significant persistent neutralizing antibody against IFN-β1 (applicable only for participants entering the study with IFN-β1 as a background DMT), in the opinion of the Investigator
- Contraindications to MRI, for example, presence of pacemakers or other implanted metal devices (excluding dental braces), an allergy to Gd, renal impairment, or claustrophobia that cannot be medically managed
- History or a positive test result at Screening for human immunodeficiency virus
- Current hepatitis C infection (defined as positive hepatitis C virus [HCV] antibody and detectable HCV Ribonucleic acid (RNA)). Participants with positive HCV antibody and undetectable HCV RNA are eligible to participate in the study (United States [US] Centers for Disease Control and Prevention)
- Current hepatitis B infection (defined as positive for hepatitis B surface antigen [HBsAg] or total hepatitis B core antibody [anti-HBc]). Participants with immunity to hepatitis B from previous natural infection (defined as negative HBsAg, positive anti-HBc, and positive hepatitis B surface antibody [anti-HBs]) or vaccination (defined as negative HBsAg, negative anti-HBc, and positive anti-HBs) are eligible to participate in the study
- History of systemic hypersensitivity reaction to BIIB061
- History of suicidal ideation or an episode of clinically severe depression (as determined by the Investigator) within 12 weeks of screening
- Clinically significant (as determined by the Investigator) 12-lead ECG or laboratory assessment abnormalities
- Any condition affecting study treatment absorption (e.g., gastrectomy)
- Treatment with statins (3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors) or proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors (e.g., alirocumab and evolocumab) within 8 weeks prior to Day 1/Baseline
- Inability or unwillingness to comply with study requirements
- Other unspecified reasons that, in the opinion of the Investigator or Biogen that make the participant unsuitable for enrollment.
Note: Other protocol defined inclusion/ exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Participants will receive BIIB061-matched placebo, orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
|
Administered as specified in the treatment arm.
Stable dose as prescribed by the physician.
Other Names:
Stable dose as prescribed by the physician.
Other Names:
|
Experimental: BIIB061 Dose 1
Participants will receive BIIB061 Dose 1 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
|
Stable dose as prescribed by the physician.
Other Names:
Stable dose as prescribed by the physician.
Other Names:
Administered as specified in the treatment arm.
|
Experimental: BIIB061 Dose 2
Participants will receive BIIB061 Dose 2 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
|
Stable dose as prescribed by the physician.
Other Names:
Stable dose as prescribed by the physician.
Other Names:
Administered as specified in the treatment arm.
|
Experimental: BIIB061 Dose 3
Participants will receive BIIB061 Dose 3 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
|
Stable dose as prescribed by the physician.
Other Names:
Stable dose as prescribed by the physician.
Other Names:
Administered as specified in the treatment arm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: First dose of study drug to end of the study (Up to Week 84)
|
An AE is any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
First dose of study drug to end of the study (Up to Week 84)
|
Overall Disability Response Score (ODRS) at Week 48
Time Frame: Baseline, Week 48
|
ODRS is a multicomponent score based on 4 components: Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test in the dominant hand (9HPT-D), and 9HPT in the nondominant hand (9HPT-ND).
It assesses overall changes in disability over time.
The 4 individual scores are added together to get the overall score that ranges from +4 to -4.
At each visit, each component is given a score relative to baseline: -1 if threshold is met for worsening, 0 if no changes meet threshold criteria, or +1 if threshold is met for improvement.
The thresholds for T25FW and 9HPT are defined by a 15% change from baseline (≥15% decrease from baseline for improvement and ≥15% increase from baseline for worsening).
For EDSS, improvement is defined as a ≥1.0-point decrease in EDSS from a baseline score of ≤6.0, and worsening is defined as a ≥1-point increase from a baseline score of ≤5.5 or a ≥0.5-point increase from a baseline score equal to 6.0.
|
Baseline, Week 48
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Normalized Magnetization Transfer Ratio (nMTR) at Week 48
Time Frame: Baseline, Week 48
|
Remyelination will be measured using magnetization transfer ratio (MTR) in chronic MS lesion detected on brain MRI.
|
Baseline, Week 48
|
Change from Baseline in Diffusion Tensor Imaging Radial Diffusivity (DTI-RD) at Week 48
Time Frame: Baseline, Week 48
|
Axon and myelin preservation will be measured using DTI-RD in chronic MS lesions detected on brain MRI.
|
Baseline, Week 48
|
Change from Baseline in Normalized T1 (nT1) Intensity at Week 48
Time Frame: Baseline, Week 48
|
Remyelination and axon preservation will be assessed by nT1 intensity in chronic MS lesions on brain MRI.
|
Baseline, Week 48
|
Change from Baseline in T1 Hypointense Volume at Week 48
Time Frame: Baseline, Week 48
|
Remyelination and axon preservation will be assessed by T1 hypointense volume in chronic MS lesions on brain MRI.
|
Baseline, Week 48
|
Percentage of Participants with 12-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND
Time Frame: Up to Week 48
|
EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability.
Scoring is based on measures of impairment in eight functional systems on examination by a neurologist.
The T25FW is a quantitative mobility and leg function performance test based on a timed walk over 25 feet.
The score for the T25FW is averaged between two completed trials.
The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs.
|
Up to Week 48
|
Percentage of Participants with 12-week Confirmed Worsening in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND
Time Frame: Up to Week 48
|
EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability.
Scoring is based on measures of impairment in eight functional systems on examination by a neurologist.
The T25FW is a quantitative mobility and leg function performance test based on a timed walk over 25 feet.
The score for the T25FW is averaged between two completed trials.
The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs.
|
Up to Week 48
|
ODRS Accounting Only for 12-week Confirmed Events of Worsening and Improvement on Respective Components over the First 48 Weeks of Treatment
Time Frame: 48 weeks
|
ODRS is a multicomponent score based on 4 components: EDSS, T25FW, 9HPT-D, and 9HPT-ND.
It assesses overall changes in disability over time.
The 4 individual scores are added together to get the overall score that ranges from +4 to -4.
At each visit, each component is given a score relative to baseline: -1 if threshold is met for worsening, 0 if no changes meet threshold criteria, or +1 if threshold is met for improvement.
The thresholds for T25FW and 9HPT are defined by a 15% change from baseline (≥15% decrease from baseline for improvement and ≥15% increase from baseline for worsening).
For EDSS, improvement is defined as a ≥1.0-point decrease in EDSS from a baseline score of ≤6.0, and worsening is defined as a ≥1-point increase from a baseline score of ≤5.5 or a ≥0.5-point increase from a baseline score equal to 6.0.
|
48 weeks
|
ODRS using 20% Threshold for T25FW over the First 48 Weeks of Treatment
Time Frame: 48 weeks
|
ODRS is a multicomponent score based on 4 components: EDSS, T25FW, 9HPT-D, and 9HPT-ND.
It assesses overall changes in disability over time.
The 4 individual scores are added together to get the overall score that ranges from +4 to -4.
At each visit, each component is given a score relative to baseline: -1 if threshold is met for worsening, 0 if no changes meet threshold criteria, or +1 if threshold is met for improvement.
The thresholds for T25FW and 9HPT are a 20% and 15% change from baseline respectively.
For EDSS, improvement is defined as a ≥1.0-point decrease in EDSS from a baseline score of ≤6.0, and worsening is defined as a ≥1-point increase from a baseline score of ≤5.5 or a ≥0.5-point increase from a baseline score equal to 6.0.
|
48 weeks
|
ODRS using 20% Threshold for T25FW, 9HPTD, and 9HPT-ND over the First 48 Weeks of Treatment
Time Frame: 48 weeks
|
ODRS is a multicomponent score based on 4 components: EDSS, T25FW, 9HPT-D, and 9HPT-ND.
It assesses overall changes in disability over time.
The 4 individual scores are added together to get the overall score that ranges from +4 to -4.
At each visit, each component is given a score relative to baseline: -1 if threshold is met for worsening, 0 if no changes meet threshold criteria, or +1 if threshold is met for improvement.
The thresholds for T25FW and 9HPT are a 20% change from baseline.
For EDSS, improvement is defined as a ≥1.0-point decrease in EDSS from a baseline score of ≤6.0, and worsening is defined as a ≥1-point increase from a baseline score of ≤5.5 or a ≥0.5-point increase from a baseline score equal to 6.0.
|
48 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Medical Director, Biogen
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antiviral Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Adjuvants, Immunologic
- Interferons
- Interferon-beta
- Interferon beta-1b
- Glatiramer Acetate
- (T,G)-A-L
Other Study ID Numbers
- 231MS201
- 2019-001847-28 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsing Multiple Sclerosis
-
BiogenWithdrawnRelapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenAbbVieTerminatedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisUnited States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
-
EMD SeronoPfizerCompletedRelapsing-remitting Multiple SclerosisUnited States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenTerminatedRelapsing-Remitting Multiple SclerosisUnited States, Spain, Germany, Australia, Sweden, Czechia, France, Italy, United Kingdom
-
Novartis PharmaceuticalsWithdrawnMultiple Sclerosis (Relapsing Remitting)
-
Genzyme, a Sanofi CompanyTerminatedRelapsing-remitting Multiple SclerosisSweden, Poland, Russian Federation, United States, Canada
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple SclerosisGermany
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States